Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 13 of 39, showing 5 Applications out of 193 total, starting on record 61, ending on 65

# Protocol No Study Title Investigator(s) & Site(s)

61.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
View

62.

ECCT/18/07/06   Hestia 3
    A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Prof Jessie Nyokabi Githanga
2. Videlis Nduba
3. Janet N Oyieko
4. Bernards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Chandaria Health Center Clinical Research Clinic (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county)
4. KEMRI Kombewa Clinical Research Centre (Nairobi City county)
5. Kondele Children\'s Hospital (Kisumu county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

63.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
View

64.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
View

65.

ECCT/24/07/04   AMC-114
    A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings       
Principal Investigator(s)
1. Dr. Naftali Busakhala
Site(s) in Kenya
Moi University Clinical Research Center
 
View